The Option Plan was last approved by the shareholders of the Company on November 7, 2025. About BioNxt Solutions Inc.BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide. BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. Investor Relations & Media ContactEmail: investor.relations@bionxt.comWolfgang ProbstCo-Founder, CFO & DirectorPhone: +49 151 25284192Hugh RogersCo-Founder, CEO & DirectorPhone: +1 604-250-6162Web: www.bionxt.comLinkedIn: https://www.linkedin.com/company/bionxt-solutionsInstagram: https://www.instagram.com/bionxtSOURCE: BioNxt Solutions Inc.View the original press release on ACCESS Newswire:https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/bionxt-solutions-announces-option-grants-1199933